#ErectileDysfunction #StemCells #SCEVs
#Andrology
Erectile dysfunction (ED) is a common male
sexual disorder, defined as the
persistent inability to achieve or maintain an
erection sufficient for sexual intercourse. It affects up to 70% of men over
the age of 70, with
increasing prevalence linked to aging, diabetes,
cardiovascular diseases, and nerve damage. ED impacts not only sexual quality
of life but also mental health and social relationships.
Current treatments primarily rely on
PDE5
inhibitors, such as sildenafil, which temporarily enhance erectile function by
increasing blood flow. However, their
efficacy is limited in patients with
organic causes of ED, as these drugs do not target underlying tissue damage.
Additionally, tolerance or side effects can arise with long-term use. In this
context,
stem cell-derived extracellular vesicles (SC-EVs) are emerging as a
promising alternative. These natural nanoparticles (30–200 nm), capable of
transporting miRNAs, proteins, and growth factors, target damaged tissues
without triggering an immune response and promote
vascular,
neural, and
muscular regeneration.
The objective of this study was to assess the
therapeutic efficacy of SC-EVs in animal models of ED, especially those induced
by diabetes, in order to explore their translational potential to clinical
settings.
Could regeneration rely on nanovesicles?
Twenty studies involving 324 rats with ED (due
to diabetes, nerve injury, or aging) were selected. The SC-EVs analyzed came
from various sources: mesenchymal stem cells (MSCs), adipose-derived stem cells
(ADSCs), urine-derived stem cells (USCs), pericytes (PCs), among others.
Results showed a
significant improvement in
erectile function after SC-EV treatment, with a strong overall effect on the
intracavernosal pressure/mean arterial pressure (ICP/MAP) ratio. SC-EVs also
enhanced the expression of NO synthase isoforms (nNOS and eNOS),
increased
smooth muscle content (α-SMA), and
improved the smooth muscle/collagen ratio in
the corpus cavernosum—indicating deep structural restoration. Subgroup analyses
revealed
no significant differences between cell types (MSC vs ADSC)
or pathological
models (diabetes vs cavernous nerve injury), suggesting a broad and robust
therapeutic effect. Although publication bias was detected, it was corrected
using the trim-and-fill method, which did not significantly alter the overall
findings.
A nanometric revolution?
ED is often rooted in vascular, neural, and
muscular damage that traditional treatments fail to adequately address. This
study aimed to evaluate whether
SC-EVs, with their regenerative potential,
could offer a more durable solution.
The findings confirm that SC-EVs operate
through
multiple biological mechanisms: activation of the NO/cGMP pathway,
oxidative stress reduction (via miR-337-3p),
anti-fibrotic modulation, neural
regeneration (NGF, NT-3), and
endothelial function enhancement. Their natural
bioavailability, low immunogenicity, and precise tissue targeting make them
ideal candidates for precision medicine in andrology.
However, the study has several limitations
warranting further research. Included studies were small in size, had short
follow-up durations (2 to 8 weeks), and displayed methodological heterogeneity
(cell types, doses, animal models). Moreover, the exact mechanisms of SC-EVs
remain partially unexplained. Large-scale clinical trials are thus essential to
validate these results, standardize EV production (under GMP conditions), and
define reproducible administration protocols.
Read next: Testosterone Replacement Therapy in Sexual Dysfunction
